Skip to main content
. 2021 Aug 15;13(8):9853–9859.

Table 5.

Clinical characteristics of other adverse events

Etomidate group (n = 90) Propofol group (n = 90) P-value Significance
During ERCP Nausea-vomiting, n (%) 2 (2.22) 3 (3.33) 1.000 n.s.
Myoclonus, n (%) 2 (2.22) 1 (1.11) 1.000 n.s.
Injection site pain, n (%) 0 (0.00) 6 (6.67) 0.029 *
After ERCP Pancreatitis, n (%) 1 (1.11) 1 (1.11) 1.000 n.s.
Cholangitis, n (%) 3 (3.33) 4 (4.44) 1.000 n.s.

n.s.: no significance; *P<0.05.